Physician profile
Michael A Lawrence
NPI 1518933415
$1,009.72
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.73 · 2021: $338 · 2022: $278 · 2023: $260 · 2024: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $366.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $292.12 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $149.61 | 2022-2023 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.10 | 2024 | Jardiance |
| Tandem Diabetes Care, INC. | $101.93 | 2021-2022 | |
| Dexcom, INC. | $89.86 | 2023 | Dexcom G7 Gss (161) |
| Abbvie INC. | $66.13 | 2021-2022 | |
| Lilly USA, LLC | $46.21 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $41.61 | 2023 | |
| Sunovion Pharmaceuticals INC. | $26.73 | 2019 | |
| Becton, Dickinson and Company | $20.65 | 2022 | |
| Amryt Pharma Holdings LTD | $19.01 | 2022 | |
| Zealand Pharma US, INC. | $18.99 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.59 | 2022 | |
| Amneal Pharmaceuticals LLC | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lawrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.